跳至主要内容
临床试验/NCT00932867
NCT00932867已完成不适用

Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment

Bayer0 个研究点目标入组 3,114 人开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
3,114
主要终点
To evaluate efficacy and safety of telmisartan in patients with arterial hypertension, who do not tolerate ACEI treatment

研究概览

简要总结

Surveillance of efficacy and safety of drug PRITOR in patieNts with arterial hypertension, who do not tolerate ACE inhibitoR treatment

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients over 18 years of age
  • Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg)
  • Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation)
  • Inclusion criteria for the control arm (treated by ACEi):
  • Patients over 18 years of age
  • Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg)
  • Patients, who tolerate ACEi treatment

排除标准

  • Cholestasis, severe hepatic insufficiency
  • Allergy to telmisartan
  • Gravidity or lactation
  • Exclusion criteria for the arm of patient treated by ACEi:
  • Cholestasis, severe hepatic insufficiency
  • Allergy to ACEi
  • Gravidity or lactation

研究组 & 干预措施

Group 1

干预措施: Kinzal/Pritor (Telmisartan, BAY68-9291) (Drug)

结局指标

主要结局

To evaluate efficacy and safety of telmisartan in patients with arterial hypertension, who do not tolerate ACEI treatment

时间窗: 1 year

次要结局

未报告次要终点

研究者

发起方
Bayer
申办方类型
Industry

相似试验